scholarly article | Q13442814 |
P2093 | author name string | Boo Sung Kim | |
Hong Soo Kim | |||
Jae Young Jang | |||
Sang Gyune Kim | |||
Soung Won Jeong | |||
Young Seok Kim | |||
Se Whan Lee | |||
Se Hun Kim | |||
Yu Ri Seo | |||
Seung Sik Park | |||
Byung Chul You | |||
Hun il Kim | |||
P2860 | cites work | [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection]. | Q50567373 |
[Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C]. | Q50568914 | ||
Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. | Q50583979 | ||
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. | Q50588396 | ||
Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C | Q27473304 | ||
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group | Q27861083 | ||
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents | Q33388340 | ||
Global challenges in liver disease | Q33999114 | ||
Prevalence of viral hepatitis markers in Korean patients with hepatocellular carcinoma | Q34656178 | ||
Risk factors for hepatitis C virus infection among Koreans according to the hepatitis C virus genotype | Q34657963 | ||
Optimal therapy of hepatitis C. | Q34984079 | ||
Epidemiology of hepatitis C virus in Korea | Q36258725 | ||
Current status of liver disease in Korea: hepatitis C. | Q37663502 | ||
Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C | Q38501611 | ||
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. | Q42608962 | ||
Antiviral action of ribavirin in chronic hepatitis C. | Q42983488 | ||
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. | Q42990082 | ||
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate | Q42999332 | ||
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin | Q43032187 | ||
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment | Q43034816 | ||
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. | Q43035939 | ||
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Q43040369 | ||
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial | Q43040967 | ||
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon | Q43048289 | ||
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment | Q44901526 | ||
Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea | Q45076673 | ||
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. | Q46866205 | ||
Differences in treatment outcome for hepatitis C among ethnic groups | Q46920864 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 3 | |
P921 | main subject | ribavirin | Q421862 |
pegylated interferon | Q7160835 | ||
virology | Q7215 | ||
P304 | page(s) | 272-278 | |
P577 | publication date | 2012-09-25 | |
P1433 | published in | Clinical and molecular hepatology | Q26853927 |
P1476 | title | A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. | |
P478 | volume | 18 |
Q37098107 | The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean. | cites work | P2860 |
Search more.